Klinikum Barnim GmbH Werner Forbmann Krankenhaus

The medical center is at the forefront of hematologic oncology, focusing on innovative treatments for various types of lymphomas. The center's research is particularly concentrated on improving outcomes for older adults with untreated Diffuse Large B-Cell Lymphoma (DLBCL).

• Diffuse Large B-Cell Lymphoma (DLBCL)
• Primary Cutaneous DLBCL Leg Type
• Intravascular Large B-Cell Lymphoma
• EBV+ DLBCL NOS
• HHV8+ DLBCL NOS
• Primary Mediastinal (Thymic) Large B-Cell Lymphoma
• B-Cell Lymphoma with Intermediate Features
• Follicular Lymphoma Grade 3B
• High-Grade B-Cell Lymphoma NOS
• High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
• T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
• DLBCL Associated with Chronic Inflammation
• ALK+ Large B-Cell Lymphoma
• Large B-Cell Lymphoma with IRF4 Rearrangement

Through the integration of acalabrutinib with R-miniCHOP, the center aims to enhance progression-free survival in patients, offering a promising alternative for those ineligible for full-dose R-CHOP therapy.